Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer’s Disease: A Pragmatic Review for Clinicians

Wyman-Chick, Kathryn A.; Chaudhury, Parichita; Bayram, Ece; Abdelnour, Carla; Matar, Elie; Chiu, Shannon Y.; Ferreira, Daniel; Hamilton, Calum A.; Donaghy, Paul C.; Rodriguez-Porcel, Federico; Toledo, Jon B.; Habich, Annegret; Barrett, Matthew J.; Patel, Bhavana; Jaramillo-Jimenez, Alberto; Scott, Gregory D.; Kane, Joseph P. M.

doi:10.1007/s40120-024-00620-x

Neurol Ther

2024

DOI: 10.1007/s40120-024-00620-x

|View full text |Cite

Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer’s Disease: A Pragmatic Review for Clinicians

Kathryn A. Wyman-Chick,

Parichita Chaudhury,

Ece Bayram

et al.

Abstract: This pragmatic review synthesises the current understanding of prodromal dementia with Lewy bodies (pDLB) and prodromal Alzheimer's disease (pAD), including clinical presentations, neuropsychological profiles, neuropsychiatric symptoms, biomarkers, and indications for disease management. The core clinical features of dementia with Lewy bodies (DLB)-parkinsonism, complex visual hallucinations, cognitive fluctuations, and REM sleep behaviour disorder are common prodromal symptoms. Supportive clinical features of… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 198 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The relationship between anticholinergic burden and frailty in the year preceding a diagnosis of dementia with Lewy bodies

Wyman‐Chick,

Barrett,

Miller

et al. 2024

Alz & Dem Diag Ass & Dis Mo

View full text Add to dashboard Cite

INTRODUCTIONLittle is known regarding the relationship between anticholinergic medications and frailty in dementia with Lewy bodies (DLB).METHODSAnticholinergic Cognitive Burden Scale (ACB) and Claims‐based Frailty Index scores were calculated for 12 months prior to the dementia diagnosis using electronic medical record and claims data. Logistic regression was used to estimate the association between ACB and odds of frailty.RESULTSCompared to controls (n = 525), a diagnosis of DLB (n = 175; adjusted odds ratio [aOR]: 15.1, 95% confidence interval [CI]: 7.0–33.9) or Alzheimer's disease (AD: n = 525; aOR = 7.7, 95% CI: 4.4–13.7) was associated with an increased odds of frailty. Patients with DLB had greater prescriptions for anticholinergic medications than patients with AD (pB < 0.001; 23% vs 9.7%). ACB was positively correlated with frailty for all groups (r = 0.30 to 0.47, p < 0.001).DISCUSSIONCumulative anticholinergic burden may be a modifiable predictor of frailty among older adults, including those newly diagnosed with dementia.Highlights Patients with newly diagnosed dementia with Lewy bodies (DLB) are more likely to have prescriptions for anticholinergic medications relative to patients newly diagnosed with Alzheimer's disease (AD) and older adults without documented cognitive impairment. In the year prior to a documented dementia diagnosis, 74% of patients with DLB and 66% of patients with AD had evidence of frailty. Anticholinergic medication burden was associated with frailty among all older adults in the study, including those without a dementia diagnosis.

show abstract

The relationship between anticholinergic burden and frailty in the year preceding a diagnosis of dementia with Lewy bodies

Wyman‐Chick,

Barrett,

Miller

et al. 2024

Alz & Dem Diag Ass & Dis Mo

View full text Add to dashboard Cite

show abstract

What is the future for dementia with Lewy bodies?

Palushaj,

Lewis,

Abdelnour

2024

J Neurol

View full text Add to dashboard Cite

Lewy Body Dementia

Galvin

2024

CONTINUUM: Lifelong Learning in Neurology

View full text Add to dashboard Cite

OBJECTIVE Lewy body dementia (LBD) is an umbrella term describing two closely related conditions: Parkinson disease dementia (PDD) and dementia with Lewy bodies (DLB). LBD is the second most common cause of neurodegenerative dementia but is often underrecognized in clinical practice. This review covers the key epidemiologic, clinical, cognitive, behavioral, and biomarker features of LBD and discusses current treatment options. LATEST DEVELOPMENTS Indicative biomarkers of LBD improve the ability to make a diagnosis and include single-photon emission computed tomography (SPECT) of the dopamine system (brain) and the noradrenergic system (cardiac), and polysomnography. α-Synuclein–specific biomarkers in spinal fluid, skin, plasma, and brain imaging are in active development with some available for clinical use. Prodromal stages of PDD and DLB have been contextualized, and diagnostic criteria have been published. An emerging theme is whether an integrated staging system focusing on protein aggregation, rather than clinical symptoms, may advance research efforts. ESSENTIAL POINTS LBD is a common cause of cognitive impairment in older adults but is often subject to significant delays in diagnosis and treatment, increasing the burden on patients and family care partners. Understanding key features of disease and the use of biomarkers will improve recognition. Earlier detection may also facilitate the development of new therapeutics and enrollment in clinical trials.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer’s Disease: A Pragmatic Review for Clinicians

Cited by 3 publications

References 198 publications

The relationship between anticholinergic burden and frailty in the year preceding a diagnosis of dementia with Lewy bodies

The relationship between anticholinergic burden and frailty in the year preceding a diagnosis of dementia with Lewy bodies

What is the future for dementia with Lewy bodies?

Lewy Body Dementia

Contact Info

Product

Resources

About